Daily Biotech Pulse: Liver Disease-Focused Gene Therapy Pact, Assembly Bio Stops HBV Infection Trial, X4 Pharma Looks For Partners
Here's a roundup of top developments in the biotech space over the last 24 hours:
Sarepta Reports One Heart Inflammation Case In Duchenne Gene Therapy Trial
Sarepta Therapeutics Inc (NASDAQ:SRPT) shared new functional data across multiple studies from the SRP-9001 (delandistrogene moxeparvovec) program for Duchenne muscular dystrophy. …
The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer’s Drug Due In January, FDA Reviews Roche’s Lymphoma Candidate, Rare Pediatric Tag For Kazia’s Pediatric Brain Cancer Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours:
Roche-AC Immune’s Crenezumab Fails To Show Benefit In Sub-Set Of Alzheimer’s Patients
Roche Holdings AG (OTC:RHHBY) said its Alzheimer’s medicine crenezumab did not slow or prevent cognitive decline in people with a specific…
Roche Releases More Evrysdi Data For Very Young Infants With SMA
Roche Holding AG’s (OTC:RHHBY) Genentech has released new long-term data on its oral drug for spinal muscular atrophy (SMA). After three…
COVID-19 Tests Boost Roche’s Q1 Sales, Reaffirms FY22 Outlook
Roche Holdings AG’s (OTC:RHHBY) Q1 FY22 sales reached CHF 16.44 billion, +10% Y/Y to (11% at constant exchange rates) on…
EMA’ Advisory Committee Recommends Approval For Roche’s Two Cancer Drugs
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended conditional approval for Roche Holdings AG’s…
FDA Warns Against Relying On Screening Tests For Prenatal Diagnosis
The U.S. FDA is warning that noninvasive prenatal screening (NIPS) tests may provide false results, such as stating a…
FDA Grants Priority Review To Roche’s Actemra For Hospitalized COVID-19 Adults
The FDA has granted priority review to Roche Holdings AG’s (OTC:RHHBY) Actemra/RoActemra (tocilizumab) for COVID-19 in hospitalized adults. “If approved, Actemra/RoActemra would…
Roche’s Tiragolumab Immunotherapy Flunks In Late-Stage Lung Cancer Trial
Roche Holding AG's (OTC: RHHBY) Phase 3 SKYSCRAPER-02 study in extensive-stage small-cell lung cancer (ES-SCLC)